Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
出版年份 2019 全文链接
标题
Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 1, Pages 113
出版商
MDPI AG
发表日期
2019-12-23
DOI
10.3390/ijms21010113
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Quantitative proteomics links the intermediate filament nestin to resistance to targeted BRAF inhibition in melanoma cells
- (2019) Marisa Schmitt et al. MOLECULAR & CELLULAR PROTEOMICS
- Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression
- (2019) Eszter Molnár et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
- (2019) Aleksandra Simiczyjew et al. Frontiers in Pharmacology
- Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents
- (2019) Alessandro Rossi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells
- (2019) S. A. Misek et al. ONCOGENE
- S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells
- (2018) Lu Ding et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Assessing stemness and proliferation properties of the newly established colon cancer ‘stem’ cell line, CSC480 and novel approaches to identify dormant cancer cells
- (2018) Faisal Alowaidi et al. ONCOLOGY REPORTS
- Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
- (2018) Ewelina Dratkiewicz et al. Oncotarget
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- Phenotype characterization of human melanoma cells resistant to dabrafenib
- (2017) Fabiola Gilda Cordaro et al. ONCOLOGY REPORTS
- Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transporters
- (2017) Yan-Rong Liu et al. Oncotarget
- Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor
- (2016) Simona Caporali et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Modes of invasion during tumour dissemination
- (2016) Pahini Pandya et al. Molecular Oncology
- Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation
- (2016) Silvana Sandri et al. PHARMACOLOGICAL RESEARCH
- MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer
- (2016) F. Pietrantonio et al. Cancer Discovery
- Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition
- (2016) Dongsheng Huang et al. Scientific Reports
- Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells
- (2015) Inna Zubrilov et al. CANCER LETTERS
- Integrin β4 and vinculin contained in exosomes are potential markers for progression of prostate cancer associated with taxane-resistance
- (2015) KYOJIRO KAWAKAMI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape
- (2015) Inna V. Fedorenko et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
- (2015) Alan E. Siroy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
- (2015) V. Paulitschke et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming Multidrug Resistance in Cancer Stem Cells
- (2015) Karobi Moitra Biomed Research International
- Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
- (2015) Melanie Sweetlove et al. Frontiers in Oncology
- B-Raf Inhibitors Induce Epithelial Differentiation in BRAF-Mutant Colorectal Cancer Cells
- (2014) R. Herr et al. CANCER RESEARCH
- Nestin depletion induces melanoma matrix metalloproteinases and invasion
- (2014) Chung-Wei Lee et al. LABORATORY INVESTIGATION
- Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment
- (2014) Yuen-Keng Ng et al. MELANOMA RESEARCH
- The clinical significance ofBRAFandNRASmutations in a clinic-based metastatic melanoma cohort
- (2013) H. Ekedahl et al. BRITISH JOURNAL OF DERMATOLOGY
- The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
- (2013) Silvy da Rocha Dias et al. EUROPEAN JOURNAL OF CANCER
- Vemurafenib Induces Senescence Features in Melanoma Cells
- (2013) Sebastian Haferkamp et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- MT1-MMP modulates melanoma cell dissemination and metastasis through activation of MMP2 and RAC1
- (2013) Khvaramze Shaverdashvili et al. Pigment Cell & Melanoma Research
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The XTT Cell Proliferation Assay Applied to Cell Layers Embedded in Three-Dimensional Matrix
- (2012) Lynn Huyck et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer
- (2012) John J. Kim et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Vinculin Activators Target Integrins from Within the Cell to Increase Melanoma Sensitivity to Chemotherapy
- (2011) E. S. Nelson et al. MOLECULAR CANCER RESEARCH
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
- (2011) Bianca Devitt et al. Pigment Cell & Melanoma Research
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now